MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Ironwood Pharmaceuticals Company Profile (NASDAQ:IRWD)

Consensus Ratings for Ironwood Pharmaceuticals (NASDAQ:IRWD) (?)
Ratings Breakdown: 6 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Hold (Score: 2.45)
Consensus Price Target: $15.28 (95.62% upside)

Current Analysts' Coverage Summary for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Show:
DateFirmActionRatingPrice TargetActions
1/8/2016WedbushReiterated RatingNeutral$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/8/2016MizuhoInitiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/11/2015BTIG ResearchInitiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2015Leerink SwannReiterated RatingHold$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015Wood & CompanyReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/6/2015BarclaysLower Price TargetEqual Weight$18.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/8/2015Cowen and CompanyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015JPMorgan Chase & Co.Lower Price TargetOverweight$23.00 -> $21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/1/2015Cantor FitzgeraldReiterated RatingHold$13.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/27/2015Bank of AmericaInitiated CoverageBuy$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/13/2015WallachBeth CapitalBoost Price TargetHold$15.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/9/2014Furey Research PartnersInitiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/29/2014AegisReiterated RatingBuy -> PositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 2/8/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha